Search Results

Ascletis Pharma Inc. announces the strategic decisions on farnesoid X receptor agonist ASC42.

Ascletis Pharma Inc. announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.

Ascletis Pharma Inc. announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase inhibitor for treatment of acne, at the 2024 American Academy of Dermatology Annual Meeting in San Diego, the United States.

Ascletis Pharma Inc. announces initiation of the Phase III clinical trial of fatty acid synthase inhibitor ASC40 for treatment of moderate to severe acne vulgaris.

Ascletis Pharma Inc. announces that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference.

Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces positive interim data from the Phase IIb expansion cohort (the “Expansion Cohort”) of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB).

Ascletis Pharma Inc. announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 for functional cure of chronic hepatitis B, and abstract poster presentation of Phase I study results of ASC41 for treatment of non-alcoholic steatohepatitis at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases.

Ascletis Pharma Inc. announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma.